Singapore markets open in 3 hours 24 minutes

I-Mab (IMAB)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.9000+0.0200 (+1.06%)
At close: 04:00PM EDT
1.9000 0.00 (0.00%)
After hours: 05:32PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.8800
Open1.9800
Bid1.4200 x 200
Ask2.2400 x 200
Day's range1.7200 - 2.0000
52-week range1.1600 - 3.3800
Volume1,062,790
Avg. volume254,619
Market cap153.678M
Beta (5Y monthly)1.10
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

    I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY). The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I-Mab a

  • GlobeNewswire

    I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

    Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitorsPhase 1 dose-escalation data demonstrated that ragistomig monotherapy can be safely administered through the highest planned doses Data will be presented at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO2024) in a poster session scheduled for June 1, 2024 at 9:00

  • PR Newswire

    I-Mab to Participate at the Jefferies Global Healthcare Conference

    I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024.